Holen Sie sich die Stockscreener-App
139.40
2.56%
-3.66
Handel nachbörslich:
139.40
Schlusskurs vom Vortag:
$143.06
Offen:
$142.11
24-Stunden-Volumen:
686.40K
Relative Volume:
1.00
Marktkapitalisierung:
$7.85B
Einnahmen:
$633.51M
Nettoeinkommen (Verlust:
$-8.10M
KGV:
-449.68
EPS:
-0.31
Netto-Cashflow:
$131.26M
1W Leistung:
-4.59%
1M Leistung:
-16.44%
6M Leistung:
+24.60%
1J Leistung:
-6.75%
1-Tages-Spanne:
$137.41
$145.43
1-Wochen-Bereich:
$137.41
$147.16
52-Wochen-Spanne:
$102.97
$175.77
Repligen Corp Stock (RGEN) Company Profile
Firmenname
Repligen Corp
Sektor
Telefon
(781) 449-9560
Adresse
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
139.40 | 8.05B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
496.12 | 175.84B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
180.62 | 48.87B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.39 | 39.53B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
259.62 | 38.39B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
45.04 | 37.69B | 27.43B | 1.27B | 1.01B | 1.5829 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Eingeleitet | HSBC Securities | Buy |
| 2025-09-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-29 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | Evercore ISI | In-line |
| 2025-02-10 | Eingeleitet | TD Cowen | Buy |
| 2024-12-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-07-20 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-03-28 | Eingeleitet | The Benchmark Company | Buy |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2021-10-14 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-11-01 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-28 | Bestätigt | First Analysis Sec | Outperform |
| 2019-08-23 | Fortgesetzt | Stephens | Overweight |
| 2019-07-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | Hochstufung | CL King | Neutral → Buy |
| 2018-11-12 | Herabstufung | CL King | Buy → Neutral |
| 2018-09-26 | Eingeleitet | H.C. Wainwright | Neutral |
| 2017-12-08 | Eingeleitet | Citigroup | Buy |
| 2017-12-05 | Eingeleitet | JP Morgan | Overweight |
| 2017-11-13 | Eingeleitet | CL King | Buy |
| 2017-10-02 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | Eingeleitet | William Blair | Outperform |
| 2017-02-13 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Repligen Corp Aktie (RGEN) Neueste Nachrichten
Impax Asset Management Group plc Reduces Position in Repligen Corporation $RGEN - MarketBeat
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Bessemer Group Inc. Sells 238,450 Shares of Repligen Corporation $RGEN - Defense World
Repligen (NASDAQ:RGEN) Upgraded to "Buy" at Wall Street Zen - MarketBeat
What Makes Repligen Corporation (RGEN) an Investment Choice? - Yahoo Finance
Repligen is Now Oversold (RGEN) - Nasdaq
A Look At Repligen (RGEN) Valuation As Ordering Stabilizes And Growth Segments Progress - Yahoo Finance
Repligen Corp (RGEN) Stock Price Down 3.37% on Jan 29 - GuruFocus
Head-To-Head Comparison: Repligen (NASDAQ:RGEN) vs. Abpro (NASDAQ:ABP) - Defense World
3 Reasons to Sell RGEN and 1 Stock to Buy Instead - Finviz
Pharma News: Can Repligen Corporation navigate macro headwindsMarket Sentiment Review & Safe Entry Point Identification - mfd.ru
UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds - Insider Monkey
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Repligen Corp (RGEN) Shares Up 3.89% on Jan 21 - GuruFocus
Single-Use Bioprocessing Market Projected to Reach US$ 122.92 Billion by 2035, Supported by Expansion of Biomanufacturing Capacity Says Astute Analytica - GlobeNewswire Inc.
Slow Capital Inc. Has $5.89 Million Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late To Consider Buying Repligen Corporation (NASDAQ:RGEN)? - Yahoo Finance
Stephens Investment Management Group LLC Grows Stock Position in Repligen Corporation $RGEN - MarketBeat
Expert Outlook: Repligen Through The Eyes Of 5 Analysts - Benzinga
UBS raises Repligen stock price target to $200 on bioprocessing recovery - Investing.com
Why Repligen (RGEN) Shares Are Sliding Today - Finviz
Repligen Corp. Seeks M&A Opportunities - marketscreener.com
Published on: 2026-01-13 17:35:09 - Bộ Nội Vụ
Conestoga Capital Advisors LLC Has $127.91 Million Position in Repligen Corporation $RGEN - Defense World
Is Repligen Corporation stock gaining market share2025 Volatility Report & Growth Oriented Trading Recommendations - ulpravda.ru
Can Repligen Corporation stock hit record highs againJuly 2025 Levels & AI Powered Market Trend Analysis - Улправда
Repligen appoints Madaus as new board chair, Hunt to retire By Investing.com - Investing.com Canada
Repligen appoints Madaus as new board chair, Hunt to retire - Investing.com
Repligen Corporation Elects Dr. Martin D. Madaus as New Chair of the Board, Succeeding Tony Hunt - Quiver Quantitative
Repligen Corp Announces New Chair of the Board - TradingView — Track All Markets
Longtime Repligen leader steps down as new board chair takes over in 2026 - Stock Titan
Repligen Corporation (RGEN): Investor Outlook with a 15% Upside Potential in the Bioprocessing Sector - DirectorsTalk Interviews
Institution Moves: How risky is Repligen Corporation RGN stock compared to peersMarket Risk Report & Risk Controlled Stock Pick Alerts - Bộ Nội Vụ
About Us - FinancialContent
Pacer Advisors Inc. Has $1.37 Million Position in Repligen Corporation $RGEN - MarketBeat
Allspring Global Investments Holdings LLC Lowers Stake in Repligen Corporation $RGEN - MarketBeat
Bioprocess Filtration Global Markets Report 2025-2030, Profiles of Leading PlayersDanaher, Merck, Sartorius, Solventum, and RepligenResearchAndMarkets.com - Business Wire
Delta Investment Management LLC Buys Shares of 50,717 Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Repligen Corporation stock remains undervaluedFibonacci Retracement Levels & Free Dynamic Capital Growth - bollywoodhelpline.com
Is Repligen (RGEN) Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins? - simplywall.st
Riverbridge Partners LLC Sells 24,644 Shares of Repligen Corporation $RGEN - MarketBeat
Congress Asset Management Co. Boosts Stake in Repligen Corporation $RGEN - Defense World
Assenagon Asset Management S.A. Takes Position in Repligen Corporation $RGEN - MarketBeat
Can Repligen Corporation stock maintain growth trajectoryFed Meeting & Smart Allocation Stock Tips - Улправда
Texas Permanent School Fund Corp Has $3.13 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat
Will Repligen Corporation stock rally after Fed decisions2025 Winners & Losers & Free Technical Pattern Based Buy Signals - Улправда
Why Repligen Corporation (RGN) stock trades below fair valueJuly 2025 Drop Watch & Risk Managed Investment Signals - Bölüm Sonu Canavarı
Repligen (RGEN): Assessing Valuation After New Chromatography Resins Expand Its Gene Therapy Toolkit - simplywall.st
How institutional buying supports Repligen Corporation stockJuly 2025 Highlights & High Accuracy Investment Signals - Улправда
Finanzdaten der Repligen Corp-Aktie (RGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):